Press Release: Pergolide has been the mainstay treatment of pituitary pars intermedia dysfunction (PPID), also known as equine Cushing’s disease, for several decades. Due to the class of drug that pergolide represents, it is a prohibited substance under Fédération Equestre Internationale and United States Equestrian Federation (USEF) rules. Currently, under USEF GR411, “Conditions For Therapeutic Administrations